A novel C2 domain binding CD33xCD3 bispecific antibody with potent T-cell redirection activity against acute myeloid leukemia

P Nair-Gupta, M Diem, D Reeves, W Wang… - Blood …, 2020 - ashpublications.org
P Nair-Gupta, M Diem, D Reeves, W Wang, R Schulingkamp, K Sproesser, B Mattson…
Blood advances, 2020ashpublications.org
CD33 is expressed in 90% of patients with acute myeloid leukemia (AML), and its
extracellular portion consists of a V domain and a C2 domain. A recent study showed that a
single nucleotide polymorphism (SNP), rs12459419 (C> T), results in the reduced
expression of V domain–containing CD33 and limited efficacy of V domain–binding anti-
CD33 antibodies. We developed JNJ-67571244, a novel human bispecific antibody capable
of binding to the C2 domain of CD33 and to CD3, to induce T-cell recruitment and CD33+ …
Abstract
CD33 is expressed in 90% of patients with acute myeloid leukemia (AML), and its extracellular portion consists of a V domain and a C2 domain. A recent study showed that a single nucleotide polymorphism (SNP), rs12459419 (C > T), results in the reduced expression of V domain–containing CD33 and limited efficacy of V domain–binding anti-CD33 antibodies. We developed JNJ-67571244, a novel human bispecific antibody capable of binding to the C2 domain of CD33 and to CD3, to induce T-cell recruitment and CD33+ tumor cell cytotoxicity independently of their SNP genotype status. JNJ-67571244 specifically binds to CD33-expressing target cells and induces cytotoxicity of CD33+ AML cell lines in vitro along with T-cell activation and cytokine release. JNJ-67571244 also exhibited statistically significant antitumor activity in vivo in established disseminated and subcutaneous mouse models of human AML. Furthermore, this antibody depletes CD33+ blasts in AML patient blood samples with concurrent T-cell activation. JNJ-67571244 also cross-reacts with cynomolgus monkey CD33 and CD3, and dosing of JNJ-67571244 in cynomolgus monkeys resulted in T-cell activation, transient cytokine release, and sustained reduction in CD33+ leukocyte populations. JNJ-67571244 was well tolerated in cynomolgus monkeys up to 30 mg/kg. Lastly, JNJ-67571244 mediated efficient cytotoxicity of cell lines and primary samples regardless of their SNP genotype status, suggesting a potential therapeutic benefit over other V-binding antibodies. JNJ-67571244 is currently in phase 1 clinical trials in patients with relapsed/refractory AML and high-risk myelodysplastic syndrome.
ashpublications.org